Core Scientific shares fell 10.8% after earnings. The likely concern is that much of the anticipated growth remains dependent on capacity still being commissioned or developed: 100 MW of CoreWeave capacity is not yet billing, and the initial 530 MW contracted by AMD is still being advanced; the transcript also provides no financing update beyond noting the substantial capital needs of AI infrastructure.
Core Scientific’s stock rose modestly by 0.8% post-earnings, reflecting investor appreciation for continued execution and capital raises but tempered by no clear breakout in guidance or margins.